Illumina, Inc. vs Kaltura Inc — how do they compare? Illumina, Inc. trades at $264.24 (market cap $40.43B), while Kaltura Inc trades at $1.32 (market cap $202.89M). The key difference: Illumina, Inc. is far larger — about 199.3× Kaltura Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Kaltura Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Kaltura Inc for 21 Days on average.
| ILMN | KLTR | |
|---|---|---|
Market Cap | $40.43B | $202.89M |
Volume | 2,948,626 | 214,400 |
Sector | Health | Technology |
52-Week High | $293.69 | $1.89 |
52-Week Low | $91.00 | $1.08 |
Typical Hold Time | 83 Days | 21 Days |
Enterprise Value | $41.79B | $215.11M |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $264.40, down 3.34% on the day but up significantly year-to-date with strong technical momentum. The stock shows bullish moving average signals and trades near pivot point resistance at $268. Fundamentally, the company has delivered three consecutive quarterly earnings beats and returned to profitability in 2025 with $850 million net income after previous losses. Recent catalysts include S&P 500 inclusion effective September 21, 2026, and growing AI integration in genomics applications.
The outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI-driven biological data expansion, while risks involve China market headwinds and elevated valuation multiples. Earnings growth and S&P 500 inclusion provide near-term catalysts, but the stock trades at premium valuations with P/E of 49.96 requiring sustained execution.
Kaltura (KLTR) trades at $1.33, up 3.91% with recent earnings beats but negative profitability. Technical indicators show bearish momentum while fundamentals reveal improving margins despite net losses. The company is gaining industry recognition for AI-powered video platforms and secured major partnerships, though cash flow remains negative.
Investment outlook balances AI innovation potential against persistent financial challenges. While analyst sentiment leans positive with 44% buy ratings, high valuation multiples and negative ROE present significant risks. The stock offers speculative appeal for investors betting on AI-driven turnaround despite current unprofitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →